We have five products that will launch in the next 12-18 months. We recently launched Yesintek in the immunology space -- a ...

Cantor Fitzgerald upgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) to a strong-buy rating in a report ...

In today’s hyper-connected healthcare environment, the supply chain has quietly become one of the sector’s most vulnerable ...

Bio-Path expects to utilize an advisory panel of AML experts to assist in the design of the final clinical development plans through potential FDA approval. Other significant milestones expected ...

Growth Hormone-Releasing Peptide-2 (GHRP-2) is a synthetic hexapeptide that has garnered significant attention in the ...

Wall Street recorded a historically strong May with the S&P 500 posting its best May performance since 1990, rising over 6% in the month, its biggest monthly gain since November 2023. The rally defied ...

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.

A Peach-Flavored Herbal Detox Tea Backed by Tradition, Modern Ingredient Science, and Daily Wellness Integration Strategies ...

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

AACE released clinical guidelines on the diagnosis, management, and surveillance of tumors related to multiple endocrine neoplasia type 1.